75 related articles for article (PubMed ID: 27148583)
1. Comprehensive characterisation of intronic mis-splicing mutations in human cancers.
Jung H; Lee KS; Choi JK
Oncogene; 2021 Feb; 40(7):1347-1361. PubMed ID: 33420369
[TBL] [Abstract][Full Text] [Related]
2. Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing.
Parker JD; Shen Y; Pleasance E; Li Y; Schein JE; Zhao Y; Moore R; Wegrzyn-Woltosz J; Savage KJ; Weng AP; Gascoyne RD; Jones S; Marra M; Laskin J; Karsan A
Cold Spring Harb Mol Case Stud; 2016 Mar; 2(2):a000679. PubMed ID: 27148583
[TBL] [Abstract][Full Text] [Related]
3. Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Monoclonal B-Cell Lymphocytosis.
Hasserjian RP
Surg Pathol Clin; 2010 Dec; 3(4):907-31. PubMed ID: 26839294
[TBL] [Abstract][Full Text] [Related]
4. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
5. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
[TBL] [Abstract][Full Text] [Related]
6. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
7. Differentiating large cell lymphoma from indolent small B-cell lymphoma in fine needle aspirates using p53, PCNA and transformed lymphocyte count.
Young NA; Ehya H; Klein-Szanto A; Litwin S; Smith MR; al-Saleem T
Acta Cytol; 2000; 44(4):592-603. PubMed ID: 10934953
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.
Laskin J; Jones S; Aparicio S; Chia S; Ch'ng C; Deyell R; Eirew P; Fok A; Gelmon K; Ho C; Huntsman D; Jones M; Kasaian K; Karsan A; Leelakumari S; Li Y; Lim H; Ma Y; Mar C; Martin M; Moore R; Mungall A; Mungall K; Pleasance E; Rassekh SR; Renouf D; Shen Y; Schein J; Schrader K; Sun S; Tinker A; Zhao E; Yip S; Marra MA
Cold Spring Harb Mol Case Stud; 2015 Oct; 1(1):a000570. PubMed ID: 27148575
[TBL] [Abstract][Full Text] [Related]
9. Non-coding recurrent mutations in chronic lymphocytic leukaemia.
Puente XS; Beà S; Valdés-Mas R; Villamor N; Gutiérrez-Abril J; Martín-Subero JI; Munar M; Rubio-Pérez C; Jares P; Aymerich M; Baumann T; Beekman R; Belver L; Carrio A; Castellano G; Clot G; Colado E; Colomer D; Costa D; Delgado J; Enjuanes A; Estivill X; Ferrando AA; Gelpí JL; González B; González S; González M; Gut M; Hernández-Rivas JM; López-Guerra M; Martín-García D; Navarro A; Nicolás P; Orozco M; Payer ÁR; Pinyol M; Pisano DG; Puente DA; Queirós AC; Quesada V; Romeo-Casabona CM; Royo C; Royo R; Rozman M; Russiñol N; Salaverría I; Stamatopoulos K; Stunnenberg HG; Tamborero D; Terol MJ; Valencia A; López-Bigas N; Torrents D; Gut I; López-Guillermo A; López-Otín C; Campo E
Nature; 2015 Oct; 526(7574):519-24. PubMed ID: 26200345
[TBL] [Abstract][Full Text] [Related]
10. Structural insight into the TRIAP1/PRELI-like domain family of mitochondrial phospholipid transfer complexes.
Miliara X; Garnett JA; Tatsuta T; Abid Ali F; Baldie H; Pérez-Dorado I; Simpson P; Yague E; Langer T; Matthews S
EMBO Rep; 2015 Jul; 16(7):824-35. PubMed ID: 26071602
[TBL] [Abstract][Full Text] [Related]
11. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.
Parry M; Rose-Zerilli MJ; Ljungström V; Gibson J; Wang J; Walewska R; Parker H; Parker A; Davis Z; Gardiner A; McIver-Brown N; Kalpadakis C; Xochelli A; Anagnostopoulos A; Fazi C; de Castro DG; Dearden C; Pratt G; Rosenquist R; Ashton-Key M; Forconi F; Collins A; Ghia P; Matutes E; Pangalis G; Stamatopoulos K; Oscier D; Strefford JC
Clin Cancer Res; 2015 Sep; 21(18):4174-4183. PubMed ID: 25779943
[TBL] [Abstract][Full Text] [Related]
12. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
[TBL] [Abstract][Full Text] [Related]
13. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.
Clipson A; Wang M; de Leval L; Ashton-Key M; Wotherspoon A; Vassiliou G; Bolli N; Grove C; Moody S; Escudero-Ibarz L; Gundem G; Brugger K; Xue X; Mi E; Bench A; Scott M; Liu H; Follows G; Robles EF; Martinez-Climent JA; Oscier D; Watkins AJ; Du MQ
Leukemia; 2015 May; 29(5):1177-85. PubMed ID: 25428260
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
